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In recent years, the functions of glial cells, namely, astrocytes and microglia, have gained
prominence in several diseases of the central nervous system, especially in glioblastoma
(GB), the most malignant primary brain tumor that leads to poor clinical outcomes.
Studies showed that microglial cells or astrocytes play a critical role in promoting
GB growth. Based on the recent findings, the complex network of the interaction
between microglial/astrocytes cells and GB may constitute a potential therapeutic
target to overcome tumor malignancy. In the present review, we summarize the most
important mechanisms and functions of the molecular factors involved in the microglia
or astrocytes–GB interactions, which is particularly the alterations that occur in the
cell’s extracellular matrix and the cytoskeleton. We overview the cytokines, chemokines,
neurotrophic, morphogenic, metabolic factors, and non-coding RNAs actions crucial
to these interactions. We have also discussed the most recent studies regarding the
mechanisms of transportation and communication between microglial/astrocytes – GB
cells, namely through the ABC transporters or by extracellular vesicles. Lastly, we
highlight the therapeutic challenges and improvements regarding the crosstalk between
these glial cells and GB.
Keywords: glioblastoma, astrocytes, microglia, crosstalk, cytokines, molecular mechanisms, microenvironmental
factors, communication mechanisms
INTRODUCTION
Glioblastoma (GB) is the most malignant primary tumor that affects the central nervous system
(CNS) (Louis et al., 2016). Besides the conventional treatment to these tumors is complex, and
based on surgery, radiotherapy, and chemotherapy with the gold-standard temozolomide (TMZ),
the GB patient’s survival rate remains about 15 months after diagnosis (Stupp et al., 2007, 2009).
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In addition, the poor efficacy of TMZ has led the scientific
community to find new therapeutic strategies that could be
used for effective GB treatment using new substances or FDA-
approved drugs against gliomas (Balça-Silva et al., 2015; Matias
et al., 2017a). However, most of these substances do not have
the ability to cross the blood–brain barrier (BBB), the biggest
challenge to the passage of chemotherapeutics to the brain
(Dubois et al., 2014). This barrier not only is composed mostly
of endothelial cells, pericytes, fibroblasts, neurons, and basal
membranes but also receives support from glial cells, such
as astrocytes and microglia (Dubois et al., 2014; Zhao et al.,
2017). During glioma progression, the BBB is compromised
that allows the entrance of immune cells from blood, which in
turn, promotes neuroinflammation. However, these alterations
induce the chemoattraction and activation of glial cells. In
fact, microglial cells produce high levels of proinflammatory
molecules, such as nitric oxide (NO) and tumor necrosis factor
alpha (TNF-α) which induce the BBB breakdown (Zhao et al.,
2017). On the other hand, the tumor cells can induce the
astrocytic activation by releasing interleukins (ILs), such as IL-1,
and consequently disrupting the astrocyte–BBB junctions (Guan
et al., 2018). Overall, these inflammatory alterations contribute to
create an imbalance in the BBB function in the context of brain
tumors like GB.
In fact, the mechanisms that support the GB’s resistance
ability have been recently discussed, and it is already known that
GB heterogeneity is a crucial reason to that resistance, due to
communication between tumor and tumor parenchyma entities
(Hambardzumyan et al., 2016).
Among various cells of the tumor microenvironment (TME),
among the glial cells, like astrocytes and the microglial cells, are
the most common cellular entities that interact with the GB and,
consequently, contribute to their tumor growth (Gieryng et al.,
2017b; Roos et al., 2017; Roesch et al., 2018).
Several studies using GB patient biopsies and in vivo animal
models showed that the tumor mass is composed of 30–50% of
glioma-associated microglia/macrophages (GAMs) (Roggendorf
et al., 1996; Olah et al., 2012; Carvalho da Fonseca et al., 2014;
Garcia et al., 2014; Zhang et al., 2015). Tumor cells have the
ability to evade immune cells by creating an immunosuppressive
microenvironment by releasing immunosuppressive factors,
such as cytokines, chemokines, neurotrophic, and morphogenic
factors, among others (Roggendorf et al., 1996; Olah et al.,
2012; Garcia et al., 2014; Zhang et al., 2015; da Fonseca et al.,
2016). In GBs, microglial cells have been shown to have a pro-
tumor phenotype that is associated with the M2-like phenotype
of macrophages due to its expression of specific factors, such
as ILs, transforming growth factor beta 1 (TGF-β1), monocyte
chemoattractant protein (MCP-1), and prostaglandin E2 (PGE-
2) (Li and Graeber, 2012). On the other hand, GBs also induce
alterations on astrocytes, turning them more reactive (Roessler
et al., 1995; Guan et al., 2018). At the same time, the glial
cells from TME also release factors that support the GB growth.
Among those factors it has been previously demonstrated that
CD11b+/Cd45-microglial cells are located around the tumor and
express arginase-1 (ARG-1), which in turn stimulates the tumor
proliferation (Zhang et al., 2015). Moreover, GB establishes direct
contact with astrocytes/microglial cells through extracellular
vesicles (EVs). EVs can transport important molecules, such
as miRNAs and cytokines, that will turn astrocytes more
reactive and, at the same time, induce M2-like phenotype
on microglial cells (van der Vos et al., 2016; Oushy et al.,
2018).
In this regard, the manipulation of microglia/astrocytes–
GB crosstalk may be on the basis of many important and
potential therapeutic strategies for the successful treatment of GB.
Recently, it has been demonstrated that targeting microglial cells
and astrocytes may be a potential tool for manipulating the GB
growth (Ye et al., 2012; da Fonseca et al., 2016).
Taking this knowledge into account, many studies have
recently focused on the identification of the principal targets and
the most useful strategies to treat GB. In glioma-bearing mice,
the blockage of CSF-1R, using the anti-CSF-1R antibody, known
as Pexidartinib (PLX3397), is observed to significantly decrease
tumor infiltration of GAMs leading to a reduction of the tumor
volume (Pyonteck et al., 2013).
In the following sections, we will describe the physiological,
biochemical, and microenvironmental functions of
microglia/astrocytes with GB cells interaction, the molecular
mechanisms underlying their crosstalk, their impact on tumor
malignancy, and how this can be translated in a therapeutic
purpose.
GLIOMAS: A DEADLY THREAT
Among the glial cells, astrocytes and oligodendrocyte precursor
cells (OPCs), which can differentiate into oligodendrocytes,
are derived from stem-like radial glial cells in ventricular and
subventricular zones during embryogenesis. Recently, one of the
hypotheses to explain the origin of gliomas has been supported
by several genetic and epigenetic mutations that occur on normal
astrocytes, oligodendrocytes, and OPCs. Consequently, these
mutations can give rise to gliomas. Among the most known
are the oligodendrogliomas, oligoastrocytomas, or astrocytomas
(Rycaj and Tang, 2015; Zong et al., 2015).
Gliomas are the most common primary malignant tumors
of CNS in adults (Thakkar et al., 2014), 50% of which is
GB. According to the World Health Organization’s (WHO)
classification, they are ranked as the most malignant astrocytoma
(Grade IV) (Ringertz, 1950; Paff et al., 2014; Urban´ska et al., 2014;
Louis et al., 2016) and will form the basis of this review.
Glioblastomas are mainly characterized by nuclear atypia,
cellular pleomorphism, mitotic activity, diffuse growth pattern,
microvascular proliferation, and/or necrosis, which constitute the
main diagnostic features (Faria et al., 2006; Urban´ska et al., 2014).
These characteristics are the result of the genomic instability and
the deregulation of several molecular signaling pathways that
culminate in a high resistance to chemotherapy (Louis et al., 2016;
Wirsching and Weller, 2016). The therapeutic approaches to GB
treatment are highly aggressive, like surgery, radiotherapy, and
chemotherapy with TMZ, the gold-standard treatment. However,
only 5% of the patients survive >5 years (Ohgaki and Kleihues,
2007; Ostrom et al., 2014).
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In this vein, the low survival of GB patients is due to
the mechanisms of resistance and high heterogeneity (Stupp
et al., 2007). This heterogeneity seems to be an indispensable
key for tumor progression, resistance, metastasis, and tumor
recurrence (Patel et al., 2014; Wang et al., 2017). Moreover,
two types of tumor heterogeneity coexist: intrinsic and extrinsic.
Currently, it is known that the intrinsic heterogeneity present
in tumors is defined by the presence of cell niches with
distinct phenotypic characteristics. It is believed by the scientific
community that the presence of a subpopulation known as
cancer stem-like cells (CSCs) is responsible for this heterogeneity.
The maintenance of the different phenotypes also depends on
the interaction with the microenvironment. These interactions
are derived from the activation of several pathways through
membrane receptors and their ligands, such as growth factors
and cytokines as the epidermal growth factor receptor (EGFR)
or IL-6, respectively. In addition, these factors are essential for
the recruitment of parenchymal cells, such as endothelial cells,
astrocytes, and microglia, that ultimately infiltrate to the tumor,
helping tumor progression, which is referred to as extrinsic
heterogeneity (Wang et al., 2009; Fonseca et al., 2012; Patel et al.,
2014).
The conventional treatments contribute to the maintenance
of GB heterogeneity. The main goals of surgery are to
establish a pathological diagnosis, relieve mass effect, and
achieve a gross total resection to facilitate adjuvant therapy
(Moiyadi and Shetty, 2012). Removing of 98%, or even
more, of the tumor mass identified in magnetic resonance
imaging (MRI) conduct to a statistically significant increase
in patient survival rate (Miller et al., 1988). Regarding
radiotherapy, it is well known that it contributes to the
proliferation of GSCs (Bao et al., 2006). In fact, the radiation
has been associated to an increased number of non-tumor
cells, such as reactive astrocytes and microglia/macrophages
in the tumor bulk (Hwang et al., 2006; Tabatabaei et al.,
2017). Recently, high levels of MCP-1, IL-8, and macrophage
inflammatory protein-1 alpha (MIP-1a), which are associated
with inflammatory response (Tabatabaei et al., 2017), were
observed in irradiated GB tissues. Our group already showed that
the TMZ does not significantly affect the glial cells proliferation,
as well as microglial cells and astrocytes (Kahn et al., 2012).
Overall, surgery, radiotherapy, and/or chemotherapy are still the
conventional therapeutic arms against GB, although they are
quite ineffective.
Altogether, the factors mentioned above, the intrinsic
heterogeneity of this neoplasia, the invasive capability, the
absence of a total tumor resection, and the enormous alterations
in the TME, which represent the extrinsic heterogeneity,
contribute to tumor resistance (Abou-Antoun et al., 2017; Arbab
et al., 2017; Roos et al., 2017).
Regarding TME, multiple factors are known to influence
the tumor aggressiveness, mainly hypoxia, the hypervascularity
in the microenvironment, and the crosstalk between GBs and
GAMs or astrocytes (Markovic et al., 2005; da Fonseca et al.,
2016; Hambardzumyan et al., 2016; Audia et al., 2017; Matias
et al., 2017b; Guan et al., 2018). In this sense, the next section
of the review will explore the role played by microglial and
astrocytes cells in modulating GB malignancy and therapy
resistance.
MICROGLIA AND ASTROCYTES’ ROLE
IN GLIOBLASTOMA MALIGNANCY
This might be one of the most exploited topics regarding TME,
and it plays the main role during tumor progression, influencing
cancer invasion, aggressiveness, and resistance (Pitt et al., 2016).
In particular, GBs are recognized as heterogeneous tumors due
to the presence of different subpopulations within the tumor
mass, some of them with distinct origin of neoplastic cells.
This heterogeneity is established by the interaction between
tumor cells and “stroma cells,” such as astrocytes and microglial
cells, which are normally responsible for the brain homeostasis
(Hambardzumyan et al., 2016; Gieryng et al., 2017b; Roos et al.,
2017; Roesch et al., 2018). Nevertheless, in the context of the
tumor, the glial and immune cells do not recognize the cancer
cells as an intruder, and so do not fight them. So how do the tumor
cells evade the immune system?
According to the histopathological and flow cytometry studies,
the human and mice glioma biopsies are composed of 30–40% of
microglial cells (Graeber et al., 2002; Garcia et al., 2014; Huszthy
et al., 2015; Annovazzi et al., 2018). Microglia is called the glial
cell; however, their origin is distinct from the other glial cells. The
microglial cells are derived from the precursors of yolk sac during
early embryogenesis instead of radial glia-like astrocytes (Del Rio
Ortega, 1932; Ginhoux et al., 2013).
In fact, the microglial cells are considered the immune cells
of the CNS (Del Rio Ortega, 1932; Ginhoux et al., 2013) since
they share macrophages characteristic of acquiring different
phenotypes depending on the pathological stimuli. For many
years, it has been considered that the M1/M2 polarization
that occurs in macrophages are also present in microglial
cells. These phenotypes have been associated with the distinct
production of pro-inflammatory or anti-inflammatory cytokines
(Hambardzumyan et al., 2016; Lisi et al., 2017). Although these
cells have a notable plasticity, and some studies showed that
microglial cells could converge between M1/M2-like phenotype
(Hambardzumyan et al., 2016; Lisi et al., 2017; Matias et al.,
2018), they can also display different protein expressions of
both M1- and M2-like phenotypes at the same time (Lisi et al.,
2014; Gabrusiewicz et al., 2016; Ransohoff and El Khoury,
2016). The expression of pro-inflammatory cytokines, such
as IL-2 and 12, interferon gamma (IFN-γ), and TNF-α, has
been associated with the M1-like phenotype. Meanwhile, the
presence of IL-10 and TNF-β is apparently associated to the M2-
like phenotype (Roessler et al., 1995; Hambardzumyan et al.,
2016; Lisi et al., 2017). However, other proteins have been
associated with the M1/M2 polarization of microglial cells. For
example, regarding the microglial cells with M1-like phenotype,
the increased levels of cytokines and ILs, such as TNF-α
and IL-12, IL-23, and IL-1β, as well as NO, were normally
observed. In parallel, the M2-like phenotype not only presents
high expression of IL-10, but also increased levels of ARG-
1, stress inducible protein (STI-1), and inducible NO synthase
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(iNOS) (da Fonseca et al., 2016; Hambardzumyan et al., 2016;
Annovazzi et al., 2018). Also, GAMs can express some markers,
such as cluster of differentiation 163 (CD163), a marker highly
specific for the M2-like phenotype (Lau et al., 2004), and CD68
that is expressed by both M1 and M2 macrophages (Holness
and Simmons, 1993). Recently, it has been described that the
transmembrane protein 119 (TMEM119) can also be used as a
specific microglia marker (Satoh et al., 2016).
In the case of GBs, glioma cells are able to suppress
the microglial M1-like phenotype and induce an M2 anti-
inflammatory phenotype through the above-mentioned
cytokines and chemokines, which in turn induce microglial
cells to release different factors that will stimulate the tumor
growth (Hambardzumyan et al., 2016; Lisi et al., 2017). Moreover,
the analysis of brain slices from a rat model of glioma using
two-color time-lapse fluorescence microscopy showed that
glioma cells induce microglia motility (Juliano et al., 2018). The
transcriptome analysis of GBs showed upregulation of genes that
are involved in the invasion capability and immunosuppression
(Mieczkowski et al., 2015; Gieryng et al., 2017a).
In fact, the immunosuppressive microenvironment in GB
occurs in various circumstances, which include the action of the
GAMs and myeloid-derived suppressor cells (MDSCs) (Chang
et al., 2016; Gieryng et al., 2017a). In the case of GBs, glioma cells
are able to stimulate GAMs to produce immunosuppressive
molecules, such as IL-10, metalloproteinases (MMPs),
chemokines as monocyte chemotactic protein-1 (CCL2),
and ARG-1, that stimulate the tumor growth (Chang et al., 2016;
Zhang I. et al., 2016; Gieryng et al., 2017b; Lisi et al., 2017).
Moreover, the presence of microglial M2-like phenotype has
been associated with the aggressiveness and poor prognosis in
GB patients (Mieczkowski et al., 2015; Iglesia et al., 2016; Gieryng
et al., 2017a). Recently, it has been shown that CCL2 released
by GB and GAMs acts as a chemoattractant to C–C chemokine
receptor type 2 (CCR2) + Ly-6C + MDSC (Chang et al., 2016).
Moreover, MDSCs have the ability to release important cytokines,
to name a few, the TGF-β and IL10, among others, inside solid
tumors, acting as immunosuppressants and promoting tumor
growth. In this sense, inhibiting MDSCs function has been
shown to promote antitumor immune responses (Zhang et al.,
2018).
Moreover, tumor-directed cytotoxic T lymphocytes function
is also regulated by immune checkpoints, such as programmed
death (PD-1) receptor and their ligands PD-L1 and PD-L2
(DiDomenico et al., 2018). Specifically, PD-L1 is highly expressed
in tumors, including gliomas. PD-L1 functions through its
interaction with correspondent receptor PD-1 in the activated
T cells. From this interaction results an inhibitory response. In
this sense, increased expression of PD-L1 in GB patients has
been correlated with poor survival of those receiving vaccine
immunotherapy (DiDomenico et al., 2018). On the other hand,
GAMs also release PD-L1 and, consequently, block the T cells
through PD-1/PD-L1 signaling (Preusser et al., 2015).
There are different types of glial cells with different origins and
ontogenies, for example, the astrocytes, as previously mentioned.
In fact, other studies have shown that tumor cells can manipulate
the behavior of astrocytes; by releasing a variety of factors,
such as IL-10 and interferon beta (IFN-β), can also stimulate
the anti-inflammatory phenotype of these cells (Guan et al.,
2018). Recently, a study demonstrated that depending on the
subpopulation of astrocytes submitted to the same oncogenic
mutation (oncogenic TRP mutations), different types of gliomas
could arise. For instance, the transformed glial fibrillary
acidic protein (GFAP)-positive astrocytes induced anaplastic
astrocytomas (WHO grade III and IV), while the transformed
glutamate/L-aspartate transporter (GLAST)-positive astrocytes
formed low-grade astrocytomas (WHO grade I) (Irvin et al.,
2017).
Thus, as described above, microglia and astrocytes appear to
be involved in various mechanisms connected to tumor growth.
Here, we will describe recent discoveries about the factors that
manipulate or may be involved in the interaction between tumor
cells and entities from TME, such as microglia and astrocytes.
The Multiple Factors Involved in
Microglia/Astrocytes–Glioblastoma
Interactions
There are several factors implicated in the microglia/astrocytes–
GB crosstalk. Among them, alterations on extracellular matrix
(ECM) components, cytoskeletal rearrangements, the cytokines,
the chemokines, the neurotrophic and morphogenic factors,
the metabolic factors, and the non-coding RNAs regulation
are the most important ones and will be described in detail
in the “The multiple factors involved in microglia/astrocytes–
glioblastoma interactions” section. The factors involved in
microglia/astrocytes–GB interactions are represented in Figure 1.
Extracellular Matrix and Cytoskeletal Modulation
During Microglia Polarization With M1/M2-Like
Phenotype and Reactive Astrocytes
During the inflammation process, there occur ECM and
cytoskeleton rearrangements in TME. It has been shown that
microglial cells are recruited to GBs by acquiring invasive
and migration abilities (Hambardzumyan et al., 2016; Wang
et al., 2017). Microglia migration and invasion capacity depend
on their M1/M2 polarization. In IL-4-treated microglial cells,
a higher migratory capacity through lower lamellipodia and
extension of membrane ruﬄes was observed, and it accompanied
a reduction of cell adhesion compared to lipopolysaccharides
(LPS)-stimulated microglial cells (Lively and Schlichter, 2013).
Indeed, the process of changing microglia cytoskeletal occurs
through the reorganization of microtubules involving the tubulin
B cofactor (TBCB), which confers different microglia phenotypes,
as described above (Fanarraga et al., 2009).
In parallel, recent studies have shown altered effects in the
contraction of actin filaments on microglia functions. Microglial
cells acquire a phagocytic phenotype through triggering receptor
expressed on myeloid cells 2 (TREM2) engagement, and
consequently, the F-actin rearrangements occur (Forabosco et al.,
2013).
Specifically, the reduction of the actin filament is related to
cellular senescence resulting in the decrease of proliferation,
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FIGURE 1 | Factors involved in microglial/astrocytic– GB cells crosstalk. (A) Astrocytic cells release IL-6 that contributes for tumor migration and invasion through the
release of MMP14s by tumors cells. The astrocytic cells released CCL20, which increases HIF-1α in GB cells via CCR6/NF-êB activation. GDNF released, by glioma
cells, also promotes astrogliosis. GB cells transfer miR-5096 to astrocytes. (B) The GB cells release interleukins (IL10, IL4, and IL13) that induce the microglial cells
to acquire M2-like phenotype. In turn, microglial cells secrete TGF-β that stimulate the glioma growth. The invasion and migration of tumor cells are stimulated by the
MMPs production by microglial cells. The tumor cells release the CCL2, which stimulates the release of IL-6 by microglia, and consequently induce the invasion of
tumor cells. Also CCL5, produced by the GB cells, increases gene expression and function of the M2 markers ARG-1 and IL-10 on microglial cells. In addition, the
GB cells express chemokine CX3CL1, which promotes the recruitment of microglial cells, through its receptor CX3CR1, and increases the expression of MMPs 2, 9,
and 14, in the tumor cells, promoting tumor invasion. GDNF secreted from gliomas acts as chemoattractant for microglia. The IL-6 produced by microglia stimulates
the expression of VEGF in tumor cells. Also, microglial cells release VEGF-A in tumor hypoxia areas. Immune brain cells express EGF in the tumor border, and thus
stimulate invasion. Wnt5a released by glioma cells induces the M2-like phenotype in microglial cells through the increase of CX3CR1, CX43, CD163, and IBA-1.
Glioma-released glucose induces the expression of GLUT5 in microglia and contributes to tumor growth. The downregulated levels of miR-142-3p are associated
with M2-like phenotype in GAMs. IL-1 induces upregulation of miRNAs in gliomas involved in inflammation, such as miR-21 and miR-146. MiR-146 is downregulated
in microglial cells and is associated with glioma growth. miRNA-21 and miRNA-451 are overexpressed in GB and are transferred to microglial cells.
migration, and phagocytosis associated to microglia events, as
well as the M2 polarization (Uhlemann et al., 2016).
In addition to the cytoskeletal changes, ECM proteins also
participate in this regulation. Xia et al. (2016) showed that
tenascin-C (TNC) produced by GB cells could modulate the
phenotype of microglial cells. In fact, the TNC knockdown,
in GB xenografts, showed that major histocompatibility
complex (MHC) class II+/ionized calcium binding adaptor
molecule 1 (IBA1)+ immune cells presented different
morphology involving fewer extensions. These alterations
represent some activated amoeboid-like microglia in the
center of the tumor mass compared to control GB xenografts,
which presents a ramified microglia, a typical phenotype
that is also observed in normal brain tissue (Xia et al.,
2016).
Moreover, Ellert-Miklaszewska et al. (2016) demonstrated
that osteopontin and lactadherin are released by GB cells
and induce the M2-like phenotype on microglial cells
by transforming those cells into amoeboid, ultimately
increasing their ARG-1 levels. Together, these authors also
observed that osteopontin and lactadherin derived from
GB cells activate integrin/FAK/PI3K signaling pathway
on microglial cells, promoting the rearrangements of
the actin cytoskeleton, and consequently inducing the
migration of the microglial cells (Ellert-Miklaszewska et al.,
2016).
Ultimately, the Fibulin-3 is an extracellular protein described
to be released by GB cells, and its expression is associated with
tumor invasiveness and proliferation. Besides, an in vivo study
showed that in the core and border of fibulin-3-overexpressed GB
occurs the activation of NF-κB in p65+ astrocytes and GB cells
(Nandhu et al., 2017).
Therefore, ECM and cytoskeletal proteins may be related to
the crosstalk between microglia/astrocytes and GB. However,
how cytoskeletal changes occur (e.g., intermediate filaments)
and what types of ECM proteins are involved (such as
laminin and collagen) in this crosstalk needs to be better
explored.
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Cytokines
Glioblastoma casts an anti-inflammatory cytokine profile by
producing vascular endothelial growth factor (VEGF), IL-10 and
IL-6, and TGF-β (Jackson et al., 2011).
Transforming growth factor beta is a cytokine that has
a dual and complex role in cancer progression, depending
on the stage of tumorigenesis and cell type (Landskron
et al., 2014). In early stages of tumorigenesis, TGF-β is a
strong inhibitor of astrocytes, epithelial, and immune cell
proliferation, by promoting apoptosis and inhibiting cell-
cycle progression (Joseph et al., 2013; Landskron et al.,
2014). This occurs mainly because of the down-regulation
of c-Myc and upregulation of cyclin-dependent kinase
inhibitor (CKI) P21 (Malliri et al., 1996). However, in later
stages, TGF-β increases metastasis and tumor invasion by
inducing glial–mesenchymal transition (GMT) (Morrison
et al., 2013). Therefore, TGF-β is a cytokine also involved
in glioma initiation, migration, and infiltration (Derynck
et al., 2001; Wick et al., 2001; Roberts and Wakefield,
2003).
Microglial cells secrete TGF-β, and its inhibition abrogates
glioma growth (Wesolowska et al., 2008). Recently, Zhu et al.
(2016) showed that TGF-β levels were twofold higher in
microglia treated with glioma-conditioned medium (G/MCM)
when compared to that in glioma-conditioned medium (G/CM),
which shows that glioma stimulates microglia to produce high
levels of TGF-β (Zhu et al., 2016).
In addition, ILs are one of the most important molecules
that regulate the immune response in the brain, and one of the
most studied is IL-10 (Lobo-Silva et al., 2016). GB suppresses the
immune response through IL-10, which is able to downregulate
the MHC II expression in microglia, impairing the proliferative
response of T cells (Frei et al., 1994).
In this sense, IL-10 acts by downregulating pro-inflammatory
cytokines in GAMs, such as IFN and TNF production (Fulton
et al., 1998).
Together with the IL-4, IL-13, and glucocorticoid hormones,
the IL-10 induces GAMs to acquire M2-like phenotype
(Mantovani et al., 2002). GAMs have been related with the
glioma progression (Ford et al., 1995; Badie and Schartner, 2000;
Coniglio et al., 2012). Cai et al. (2015) identified six cytokine
signatures among a group of glioma patients with poor survival
prognosis. Additionally, the authors related those cytokines with
the M2-like phenotype, such as high levels of mRNA encoding
IL-10 and TGF-β1, with the glioma progression (Cai et al., 2015).
Altogether, it has been suggested that GAMs release MMPs
related to tumor invasion, specifically the MMP-2 and membrane
type-1 (MT1)-MMP (Osenkowski et al., 2004; Mayes et al.,
2006).
Another cytokine highly regulated in GB samples is IL-6
(Tchirkov et al., 2001). It has been shown that CCL2, produced by
tumor cells, increases IL-6 levels released by microglia, which are
associated to GB invasiveness and growth in a TLR4-dependent
manner (Goswami et al., 1998; Wang et al., 2009; Zhang et al.,
2012; a Dzaye et al., 2016). During the tumor invasiveness, IL-6
levels released by microglia increase MMP-9 levels (Yeung et al.,
2013).
Interleukin-6 is also responsible for inducing VEGF synthesis,
and both cytokines are able to induce tumor angiogenesis (Cohen
et al., 1996; Huang et al., 2004).
The pro-angiogenic cytokine, VEGF, has been correlated
with a poor prognosis and GB recurrence (Turkowski et al.,
2018). GBs are recognized as highly angiogenic tumors (Brem
et al., 1972). Besides GBs, GAMs are also able to produce
VEGF (Chen et al., 2014; Brandenburg et al., 2016). In
fact, Osterberg et al. (2016) demonstrated that VEGF is
expressed not only in glioma blood vessels but also in
tumor areas enriched with CD14+/CD68+ immune cells.
Moreover, they also observed that in glioma hypoxia areas,
the GAMs are responsible for VEGF-A production (Osterberg
et al., 2016). Interestingly, it has been described that the
inhibition of VEGF together with angiopoietin-2 (Ang-2)
induce the polarization of GAMs to M1-like phenotype, as
well as increase mice survival and delay the tumor growth
(Kloepper et al., 2016). On the other hand, a decrease in
GAMs infiltration was observed, followed by augmentation of
apoptosis and MHC expression in VEGF-overexpressing gliomas,
suggesting a regulatory feedback mechanism (Turkowski et al.,
2018).
Overall, microglial cells are not the only glial cells that release
IL-6, astrocytes too expressed high amounts of IL-6, in particular
when co-cultured with GB cell lines, contributing to tumor
migration and invasion through the release of the active form of
MMP-14 by GB cells (Chen W. et al., 2016).
In this manner, cytokines represent crucial factors involved in
microglia/astrocytes–GB crosstalk as represented in Figure 1.
Chemokines
The chemokines are highly expressed by microglia and astrocytes
and are mainly important to their recruitment and activation in
cancer (Hattermann and Mentlein, 2014; Laudati et al., 2017; Jin
et al., 2018).
Chemokine axes, such as fractalkine (CX3CL1)/CX3CR1,
C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C chemokine
receptor type 4 and 7(CXCR4/CXCR7), CCL2/CCR2, and
CCL5/CCR5, are clearly involved in tumor progression (Held-
Feindt et al., 2010; Hattermann and Mentlein, 2014; Laudati et al.,
2017).
Glioma-associated microglia/macrophages are characterized
by the expression of those chemokines or receptors (Hattermann
et al., 2014). And if the expression of GAMs M2-markers is
decreased, this significantly increases survival and suppresses the
growth of established tumor (Pyonteck et al., 2013).
In the brain, the neurons and astrocytes produce CX3CL1,
and the receptor is restricted to microglia (Ludwig and Mentlein,
2008; Ransohoff and El Khoury, 2016). The CX3CL1 expressed
by GB cells induces the human GAMs recruitment through
its receptor CX3CR1 and increases the expression of matrix
MMPs 2, 9, and 14 in GAMs, which consequently promotes the
tumor invasion (Held-Feindt et al., 2010; Carvalho da Fonseca
and Badie, 2013; Ferrer et al., 2018). In humans, but not in
rodent models, the prolonged average of survival time of glioma
patients and the low infiltration of microglia is associated with the
CX3CR1 gene (Liu et al., 2008; Rodero et al., 2008).
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In turn, CXCL12 is widely produced in gliomas and normal
brain. In tumor areas with necrosis, angiogenesis, and invasion,
the GSCs express mainly the CXCR4 (Hattermann and Mentlein,
2014). ALTS1C1 cells, a new murine glioma model, expressed
a relatively high level of CXCL12 in vitro and in vivo. The
inhibition of CXCL12 by a specific siRNA has reduced tumor
infiltration, and the formed tumors had defined borders. In
addition, the inhibition of CXCL12 synthesis reduced migration
of GAMs toward hypoxia regions (Wang et al., 2012). Therefore,
the alteration of CXCL12-concentration gradient could be an
important approach for the tropism of GAMs toward hypoxia
areas (Hattermann and Mentlein, 2014). In the last decade,
several preclinical studies in glioma models have shown that
the impairment of the CXCL12/CXCR4 signaling using specific
antagonists reduces tumor growth, angiogenesis, and recurrence,
suggesting that this approach represents a promising strategy for
GB therapy (Tseng et al., 2011; Liu et al., 2014).
The CCL2 was firstly detected in glioma cell supernatants
and confirmed to be a chemoattractant protein for immune cells
in vitro (Yoshimura et al., 1989). The astrocytes and microglia
are the main sources of CCL2 in CNS (Vakilian et al., 2017).
In GBs, the CCL2 expression is correlated with GAMs by
recruitment of regulatory T cells and MDSCs to increase GB
growth (Hattermann and Mentlein, 2014; Chang et al., 2016).
Specifically, the glioma growth is induced by the IL-6 levels,
which are produced by microglial cells under stimulation of
glioma-released CCL2 that acts upon CCR2 in microglia. The
CCL2–CCR2–IL-6 pathway is considered a potential therapeutic
target for gliomas (Zhang et al., 2012). In addition, an
interesting study demonstrated that astrocytes enhance the
invasion of CD133+ GSCs, providing a microenvironment
rich in cytokines and chemokines, such as CCL2 (Rath et al.,
2013).
In addition to the chemokines mentioned above, the amounts
of CCL5 and CCR5 expression are correlated with poor prognosis
and average survival time of GB patients (Laudati et al., 2017).
Moreover, GAMs produce CCL5 and, consequently, potentiate
the regulation of neurofibromatosis type 1 (NF1), associated with
a murine low-grade optic glioma growth (Solga et al., 2015).
CCL5 produced by the GB cells acts by increasing its cell survival
using CD44 as a receptor, to suppress programmed cell death
(Pan et al., 2017). Interestingly, Laudati et al. (2017) found
that maraviroc (MRV), a CCR5 blocker, reduced the M2-like
markers ARG-1 and IL-10 levels and function. In addition, the
inhibition of CCR5 was correlated with a significant decrease
of microglia migration, provoked by the inhibition of PI3-AKT
pathway (Laudati et al., 2017).
It is already known that astrocytes–GB interactions can occur
through the CCLs and ILs. In hypoxic conditions, the astrocyte-
released CCL20 increases hypoxia-inducible factor 1-alpha (HIF-
1α) in GB cells via CCR6/nuclear factor kappa B (NF-κB)
activation and, in turn, induces GB cells to adapt to hypoxia (Jin
et al., 2018).
Taken together, the communication network established
among gliomas cells with TAMs and astrocytes cooperates
through the chemokines (Figure 1) to increase glioma growth
and infiltration into brain parenchyma, contributing to poor
patient survival, and therefore, blockage of these pathways could
assist in better therapy options for these patients.
Neurotrophic and Morphogenic Factors
During the last few years, the neurotrophic factors (NTFs) have
gained importance due to their function of not only growth,
differentiation, and survival of both mature and developing
neurons (Ku et al., 2013; Liu et al., 2013) but also in modulation
of microglial cells and astrocytes activity (Tanaka et al., 2008;
Xu et al., 2018). The NTFs could be divided into six families
(Table 1).
Moreover, it has been reported that glial-derived neurotrophic
factor (GDNF) receptors, namely, GFRa-1 and GFRa-2, are
expressed by microglial cells (Honda et al., 1999; Rickert et al.,
2014). Ku et al. (2013) showed that the GDNF secreted from
gliomas acts as a chemoattractant for microglia. In this study,
the authors showed that mice xenografts of glioma cells silenced
to GDNF reduced the GAMs and generated smaller tumors.
Additionally, the GDNF released by glioma cells also promotes
astrogliosis; in spite of the downregulation of GDNF, they did
not observe any differences in astrocytes that surrounded the
tumor mass (Ku et al., 2013). Besides that, GB, as well as
microglial cells, secretes cytokine TGF-β, which is important
to stimulate tumor cell invasion (Han et al., 2015; Kim et al.,
2017). Furthermore, TGF-β in the presence of oncolytic herpes
simplex viruses (oHSV) plays an anti-inflammatory role during
glioma progression by decreasing the percentage of immune
cells (CD45+CD11b+) and, consequently, reducing their NO
synthase 2 (NOS2) and TNF-α mRNA and protein levels involved
in M1-like phenotype on microglial cells (Han et al., 2015).
On the other hand, GSCs become more invasive, thereby
promoting glioma progression in response to the TGF-β1
secreted by the CD11b+F4/80+ immune cell population (Ye
et al., 2012).
Moreover, TGF-β can be associated with the VEGF expression,
which is important not only for tumor vascularization but also
in the modulation of macrophages/microglial cells activity (Roy
et al., 2015). Recently, it has been demonstrated that high levels
of VEGF induce GB progression and a marked remodeling of
the vascular structure accompanied by an important reduction
of IBA1+ cells. However, less accumulation of IBA1+ cells at
the perivascular niche induced a reduction of pro-angiogenic
factors (such as VEGF) released, suggesting a possible regulatory
feedback mechanism (Turkowski et al., 2018). The authors also
suggested that during an anti-VEGF therapy and standard VEGF
expression, the tumor might manipulate microglia/macrophages
to collaborate in angiogenesis (Turkowski et al., 2018).
Other NTF, such as colony stimulating factor-1 (CSF-1) and
EGF, are also important to microglia–GB crosstalk (Pyonteck
et al., 2013; Komohara et al., 2016; Kim et al., 2017). CSF1 acts
as an oncogene by inducing gliomagenesis. Moreover, it was
observed that the periphery of tumor mass of high-grade gliomas
presents a minority population of GAMs that express ARG1 and
CD206, typical markers for M2 polarization (De et al., 2016).
Further, the IBA1+ and CD163+ immune brain cells express EGF
in the tumor border and thus stimulate the tumor cells to invade
the parenchyma (Komohara et al., 2016; Hide et al., 2018).
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 August 2018 | Volume 12 | Article 235
fncel-12-00235 August 2, 2018 Time: 11:24 # 8
Matias et al. Microglia/Astrocytes–Glioblastoma Molecular Crosstalk
TABLE 1 | Neurotrophic and morphogenic factors involved in modulation of microglia/astrocytes phenotype in GB context.
Family Type of factors Hallmarks References
Neurotrophic
factors
Neurotrophins Brain-derived neurotrophic
factor (BDNF)
The BDNF derived from the brain-stimulated
microglial cells to produce IL-15 and
consequently increase NK cell infiltration and
activation, contributing to limit glioma expansion.
(Garofalo et al., 2017)
Nerve growth factor (NGF) NGF is expressed by glioma cells. Microglia
expresses NGF receptors and when exposed to
NGF, acquire neuroprotective and
anti-inflammatory phenotype through modulation
of motility, phagocytosis, and degradation
pathways. No data in microglia–GB crosstalk.
(Lawn et al., 2015; Rizzi
et al., 2018)
Neurotrophin-3 (NT-3) NT-3 is important for the proliferation of brain
tumor-initiating cells. Microglial cells express
NT-3. No data in microglia–GB crosstalk.
(Zhang et al., 2009; Forsyth
et al., 2014)
CNTF Ciliary neurotrophic factor
(CNTF)
CNTF is synthesized and secreted by gliomas and
inhibits T-cell activation and microglia activation.
Microglia express CNTF receptor alpha (CNTFRα)
and its stimulation with CNTF induces COX2
expression. CNT and CNTFα are expressed by
astrocytes. No data in astrocytes–GB crosstalk.
(Dallner et al., 2002; Lin
et al., 2009; Olah et al.,
2012)
GDNF Glial cell line-derived
neurotrophic factor (GDNF)
Microglia and astrocytes express GFRa-1 and
GFRa-2. Glioma-released GDNF acts as
chemoattractant for microglia and did not induce
astrogliosis.
(Ku et al., 2013)
Ephrins Ephrin-B3 Ephrin-B3 is highly expressed in GBs. Astrocytes
express EphB3/EphA4 receptors. No data in
astrocytes–GB crosstalk.
(Zhuang et al., 2011; Royet
et al., 2017)
EGF and TGF Transforming growth factor
beta (TGFβ)
Reactive astrocytes have shown to secrete
TGF-β, which increases the proliferation and
invasion of tumor cell.
(Zhang et al., 2015)
Vascular endothelial growth
factor (VEGF)
High levels of VEGF induce GB progression and a
marked remodeling of the vascular structure
accompanied with an important reduction of
microglial cells.
(Turkowski et al., 2018)
Others Macrophage colony-stimulating
factor (M-CSF)
M-CSF [also named colony-stimulating factor 1
(CSF-1)] promotes the upregulation of several M2
markers and thereby actively contribute to the
M2-like GAM polarization.
(Komohara et al., 2008)
Granulocyte–macrophage
colony-stimulating factor
(GM-CSF)
Microglia and astrocytes express GM-CSF
receptor, GM-CSF induces an inflammatory
response through IL-1β, TNFα, IL-10, and IL-6
increased levels. GM-CSF is secreted by glioma
cells and induces GAM (IBA1+ cells) invasion.
(Sielska et al., 2013; Nicol
et al., 2018)
Morphogenic
factors
Hedgehog Sonic Hedgehog (Shh) Reactive astrocytes-released Shh drives
proliferation of IBA1+ immune cells
(microglia/macrophages). LPS-treated microglial
cells induce Shh expression. GB also secrete
Shh. No data in microglia/astrocytes–GB
crosstalk.
(Pitter et al., 2014; Rimkus
et al., 2016; Lee et al.,
2017)
Wingless-type MMTV
integration site
Wnt5a GB-released Wnt5a increase infiltration of the
immune cells (microglia). No data in
astrocytes–GB crosstalk.
(Dijksterhuis et al., 2015)
family (Wnt) Wnt3a Microglial cells and astrocytes express Frizzled
(FZD) and LRP5/6 receptors. Wnt3a is highly
expressed in GB cells. No data in
microglia/astrocytes–GB crosstalk.
(Halleskog et al., 2011;
Denysenko et al., 2016)
Moreover, brain-derived neurotrophic factor (BDNF) is a
very interesting NTF in the tumor context. GAMs, stimulated
by brain-released BDNF, induced IL-15 production and,
consequently, increased NK cells’ infiltration and activation,
contributing to limit glioma expansion (Garofalo et al.,
2017).
Nevertheless, the morphogenic factors also play important
roles in microglia/astrocytes–glioma crosstalk, mainly, the
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 August 2018 | Volume 12 | Article 235
fncel-12-00235 August 2, 2018 Time: 11:24 # 9
Matias et al. Microglia/Astrocytes–Glioblastoma Molecular Crosstalk
wingless-type MMTV integration site family (WNT) and sonic
hedgehog (SHH). During early embryogenesis, these two factors
are crucial for proper development of the tissues and organs
(Matias et al., 2017b; Carballo et al., 2018). However, these
pathways are recapitulated and play crucial roles during tumor
development. Moreover, its influence on the immune system has
also been highlighted over the last few years (Matias et al., 2017b).
In the TME, it was demonstrated that SHH is important for
controlling epithelial–mesenchymal transition (EMT) – through
a paracrine and autocrine manner – the pathogenesis, and
progression of tumors, such as brain and prostate cancers
(Tzelepi et al., 2011; Islam et al., 2016; Ming et al., 2017). In
case of brain tumors, a study showed that in SHH subgroup
of medulloblastoma, the tumor-macrophages/microglial cells
might contribute to tumor growth, which has already been
suggested as a potential therapeutic approach (Margol et al.,
2015). Besides, it is already known that GB could secrete SHH
(Rimkus et al., 2016). Additionally, reactive astrocytes can secrete
Shh, inducing the proliferation of microglia, oligodendrocyte
transcription factor (OLIG2) positive progenitors, and astrocytes
after a neurodegeneration process (Pitter et al., 2014). However,
the role of SHH from the GB cells in microglia and astrocytes
proliferation and activation remains unclear.
Besides, it has been observed that SHH also interacts with
other signaling pathways normally activated in tumors, including
brain tumors, such as TGF-β and the canonical WNT pathway
(Carballo et al., 2018). It has been suggested that the WNT
components can also be regulators of microglia–GB interactions
(Matias et al., 2018). Both microglial and astroglial cells express
high levels of WNT and FRIZZLED (FZD) receptors and play
major roles in the modulation of the inflammatory response
and cellular mechanisms, such as proliferation, migration, and
invasion (L’Episcopo et al., 2018).
It has been described that during the inflammatory response
in different contexts, the canonical and non-canonical WNT
signaling pathways – more specifically, WNT3a and WNT5a –
have a great relevance (Halleskog and Schulte, 2013; Silva-García
et al., 2014; Suryawanshi et al., 2015; Chen K. et al., 2016).
Recently, it was suggested that WNT5a plays a crucial role in
the interaction of the tumor with microglia. In silico studies,
using GB samples from the TCGA and immunohistochemistry
of human biopsies (TMAs), have shown that gliomas have
high expression of WNT5a and that this aberrant expression
is associated with the presence of immune cells. Moreover,
this study showed that different groups, according to WNT5a
expression, have different gene patterns. The glioma groups with
high expression of WNT5a presented high levels of CX3CR1,
connexin 43 (CX43), CD163, and IBA-1, suggesting that the GB-
infiltrating microglial cells are activated, which represent the M2-
like phenotype. In addition, signaling pathways associated with
the inflammatory response, such as toll-like receptors (TLRs),
were identified (Dijksterhuis et al., 2015). Furthermore, it has
been suggested that microglia may be one of the signaling entities
for breast cancer cell metastases in the brain, since the microglia
of organotypic brain cultures produce high levels of Wnt5a,
promoting the growth of breast cancer (Pukrop et al., 2010; Nayak
et al., 2012).
The glioma microenvironment can promote the activation
of reactive astrocytes characterized by high expression of GFAP
and the glycoprotein podoplanin. Lu et al. (2016) showed that
tumor-associated astrocytes (TAAs) exhibited high-migration
and invasion capability through the induction of GMT by
increasing vimentin and MMP levels, which are WNT target
proteins. Moreover, they observed that WNT/β-catenin signaling
pathway is activated in TAAS, suggesting that glioma cells induce
the activation of TAAS via WNT/β-catenin signaling (Lu et al.,
2016).
Altogether, the NTFs and morphogenic factors may also
influence the immune system in tumors and, therefore, could
be potential targets for tumor therapies (Figure 1). This subject
still needs to be further exploited to address the role of these
molecules in this crosstalk.
Metabolic Factors
In the last decades, some studies tried to understand how the
metabolism of the CNS cells behaves in different physiological
context, such as inflammation and cancer.
All types of cells need vast amounts of adenosine triphosphate
(ATP) to survive, including microglia and astrocytes (Davalos
et al., 2005; Engl and Attwell, 2015; Jackson and Robinson,
2018). Depending on the oxygen conditions, cells can produce
ATP by the conversion of glucose to pyruvate through the
mitochondrial tricarboxylic acid cycle (TCA) and glycolysis.
On the other hand, in the absence of oxygen (hypoxia), cells
transform the pyruvate into lactate by anaerobic glycolysis
(Orihuela et al., 2016; Ghosh et al., 2018). Therefore, the
study of the metabolic alterations that occur in microglia and
astrocytes can be important in understanding the microglia
polarization of M1–M2 and the astrocytes reactivity that occurs
in GB.
During the polarization of M1/M2-like phenotypes in
microglial cells, some alterations occur in metabolic circuits
and mitochondrial respiration (Orihuela et al., 2016). Microglia
express different transporters for main metabolites, such as
glucose, glutamine, and fatty acids (Ghosh et al., 2018). One of
the proteins that regulate the independent transport of glucose
in microglia, and also in tumor cells, is the family of glucose
transporter (GLUT) (Sasaki et al., 2004). Sasaki et al. (2004)
showed that the GAMs express GLUT5 in non-necrotic areas
of the tumor. Moreover, the microglial cells, under glucose
deprivation (GD), increase the secretion of IL-6 (Choi et al.,
2015) as well as their phagocytic behavior (Churchward et al.,
2018). Taking into account that IL-6 and phagocytosis have been
associated to M1-like phenotype in microglia (Hambardzumyan
et al., 2016), the downregulation of glucose levels in GB or
even the inhibition of GLUT5 may be useful to induce M1
polarization in microglial cells and, consequently, reduce the
tumor aggressiveness.
The energy potential of mitochondria and other organelles
for the cellular energy production machinery is indisputable
since it participates in different fronts by performing various
actions. Among them are the control of cytosolic calcium (Ca2+)
levels, the control of apoptosis through the transition of pore
permeabilization, the reduction–oxidation modulation (redox),
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and the production of reactive oxygen species (ROS) (Wallace,
2012).
The variation of the internal Ca2+ levels, the cellular stress, or
the decrease in the number of copies of the mitochondrial
DNA can cause alterations of the membrane potential.
Normally, the absorption of Ca2+ by the membrane of
the mitochondria inhibits apoptosis of the cells and also
induces high levels of ROS, which consequently leads to
neoplastic transformation of the cells. However, high levels
of ROS induce cellular apoptosis and necrosis because of
its cellular toxicity. The increase of Ca2+ levels occurs
in the cytoplasm compartment, which induces activation
of Ca2+ signaling pathways that regulate tumorigenesis
and invasive tumor growth (Gupta et al., 2012; Wallace,
2012).
Recently, it has been under discussion that the metabolic
alterations contribute to the aggressiveness of the tumors,
through the dysregulation of mitochondrial and cytoplasmic
enzymes, such as enzyme isocitrate dehydrogenase (IDH)
(Al-Khallaf, 2017). Particularly in gliomas, the presence of
mutations in this enzyme, which has been associated to better
prognosis and survival, comparably to IDH wild-type, has been
reported (Louis et al., 2016). Normally, IDH1 is present in the
cytoplasm and interfere with the catalyzation of isocitrate (ICT)
into α-ketoglutarate (α-KG) to produce nicotinamide adenine
dinucleotide phosphate (NADPH) from NADP+. Instead, IDH2
regulates the reverse reaction of α-KG into ICT in mitochondria
(Al-Khallaf, 2017).
However, the presence of the mutations, IDH1-R132 and
IDH2-R172, causes the reduction of α-KG and an increase of R-
2-hydroxyglutarate (2HG) levels, an oncometabolite that induces
alterations on chromatin and histone methylation (Ward et al.,
2010; Koivunen et al., 2012; Amankulor et al., 2017).
How the IDH mutations interfere/modulate the TME has
also been addressed in the literature. For instance, a study
using a cohort of 60 patients with gliomas with IDH1–R132H
mutation was performed to understand if the GAMs samples
also have the IDH1–R132H mutation. The authors showed
that a population of CD68+, IBA1+, and CX3CR1+ GAMs
samples also had the IDH1–R132H mutation (Zheng et al., 2012).
Moreover, mice with IDH1–R132H mutation showed elevated 2-
HG and deoxyribonucleic acid (DNA) methylation, as well as
reduced immunological characteristics, such as reduced number
of microglial cells (Zhang X. et al., 2016; Amankulor et al., 2017).
However, the IDH mutations might occur in a subgroup of
GB. Turcan et al. (2012) showed that IDH1 mutation modulates
the differentiation state by increasing the nestin levels in normal
human astrocytes (NHAs). Moreover, these IDH1 mutant cells
produce higher levels of 2-HG, which is normally observed in
low-grade brain tumors. According to the literature, the IDH
mutation in cancer patients is associated with better prognostic
and survival rate, suggesting that IDH could be a promising target
to reduce the aggressiveness of GB by modulating the astrocytes
activity (Turcan et al., 2012).
Thus, we hypothesize that alterations in TCA cycle and
glycolysis can induce the impairment of aggressiveness of
the tumor and pro-inflammatory response (Figure 1) and be
visualized as a possible target to establish new therapeutic
strategies to combat the gliomas.
Microglia/Astrocytes and Glioblastoma: The Role
Played by Non-coding RNAs
It is well known that RNA biology plays an important role in the
CNS where robust expression of non-coding RNAs (ncRNAs) has
been found. The ncRNAs are widely defined as all types of RNA
that cannot be translated into proteins due to the lack of open-
reading frames (ORFs). They can be small ncRNAs (snRNAs) and
long ncRNAs (lncRNAs) (Qureshi and Mehler, 2012; Aprea and
Calegari, 2015; Ji et al., 2015; Quan et al., 2017).
The microRNAs (miRNAs) are snRNAs capable of regulating
gene expression in cancer cells and associated normal cells (Pitt
et al., 2016). Their unique features include regulation of multiple
targets, ability to be secreted into the extracellular space, and
the communication linking capacity between tumor cells and
the TME. Therefore, studying miRNAs concerning the complex
interactions between the tumor cells and their microenvironment
is necessary for understanding the tumor progression and, thus,
the development of new therapeutic strategies (Kros et al., 2014;
Kohlhapp et al., 2015; Li and Liu, 2016).
Interestingly, the dysregulation of miRNAs in GAMs has
been shown to promote tumorigenesis. For instance, the miR-
155 is a well-known regulator of the immune response and is
involved with the M1/M2 polarization of macrophages/microglia
(Cardoso et al., 2012). In the same context, studies that induce
the pro-inflammatory phenotype in cultured microglia using LPS
demonstrated an increased expression of miR-155 and miR-146
and a decreased expression of miR-689 and miR-124, of which
miR-124 was associated with microglia quiescence (Ponomarev
et al., 2013; Caldeira et al., 2014; Cunha et al., 2016). Notably,
miR-155 was discovered to be constantly downregulated in
immune cells, thus promoting tumorigenesis (He et al., 2009).
Another miRNAs have been found to be downregulated within
GAMs, including the miR-142-3p and miR-146b-5p (Xu et al.,
2014; Zhang et al., 2017). Consequently, the downregulation of
miR-146b-5p was found to promote tumor proliferation and
invasion ability (Cai et al., 2015) while the downregulation of
miR-142-3p is associated with M2-like phenotype in GAMs.
In vivo study has shown that the administration of miR-142-
3p induced the polarization of GAMs into M1-like phenotype,
and consequently, the GB growth was reduced and the median
survival rate increased (Xu et al., 2014).
Elsewhere, IL-1-induced miRNAs involved in inflammation,
such as miR-21 and miR-146, have been found to be upregulated
in low-grade gliomas (Tili et al., 2011; Prabowo et al., 2015).
In line with the previous thoughts, characterization of miRNA
at the TME border can help to improve prognosis in GB patients.
A miRNA expression study conducted using samples from the
surrounding tissue of GB mass showed that miR-338-3p, miR-
219-2-3p, miR-27b, miR-23b, and miR-219-5p were upregulated
while miR-H18, miR-1246, miR-1181, miR-3195, miR-630, miR-
642b, and miR-3663-3p were downregulated in the tumor border.
Subsequently, miR-338-3p, miR-219-5p, and miR-219-2-3p were
correlated to oligodendrocyte differentiation. The number of
oligodendrocyte lineage cells was high in the border where
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 August 2018 | Volume 12 | Article 235
fncel-12-00235 August 2, 2018 Time: 11:24 # 11
Matias et al. Microglia/Astrocytes–Glioblastoma Molecular Crosstalk
macrophages and microglia were also colocalized. Moreover, it
was observed in tumor mass border that increased levels of EGF,
heparin-binding EGF-like growth factor (HB-EGF), IL-1β, and
acidic fibroblast growth factor (FGF1) that correspond to the
presence of OPCs and macrophages/microglia are responsible for
inducing stem-like phenotype and resistance in GB cells (Hide
et al., 2018; Figure 1).
Moreover, in GBs, many well-known miRNAs that are highly
expressed (let-7a, miR-16, miR-21, miR-27a, miR-26a, miR-
93, miR19b, miR-320, miR-20, miR-15b, and miR-92) in the
microvesicles are isolated from patients. In this sense, an analysis
of miRNAs transference through GB-isolated EVs to microglial
cells showed that microglia had taken up these EVs, which
increased the levels of miR451/miR21 to 15-fold (van der
Vos et al., 2016). This means that probably miRNAs that are
overexpressed in GB can be transferred to microglial cells by EVs
(Figure 2).
Parallel to this, microRNAs can also be transferred between
different cells in the TME through the gap junctions. Astrocytes
have been shown to form gap junctions with glioma cells (Zhang
et al., 1999), which then can potentially assist in tumor invasion.
This was demonstrated by a study that found out that the glioma
invasion was reduced by the gap junctions formed between
glioma cells, while glioma-astrocyte and astrocyte-astrocyte gap
junctions promote glioma invasion, at least in part, by the glioma-
transferred miR-5096 to astrocytes (Hong et al., 2015).
In addition to its function in microglial cells as described
above, the miR-146 is also a negative regulator of astrocyte-
mediated inflammation (Iyer et al., 2012). Upregulation of this
miRNA has been correlated with a reduced expression of its
target, the TNF receptor associated factor (TRAF6), which is
involved in a number of seizures in glioma patients. This suggests
that miR-146 could be involved in the epileptogenic focus
surrounding the tumor (Prabowo et al., 2015).
These studies support the role played by non-coding RNAs
in facilitating intercellular communication between immune
cells and GB, although their precise contribution in modulating
microglia/astrocytes activity in the context of GB still has to be
fully elucidated.
Mechanisms of Transportation and
Communication Between
Microglial/Astrocytes–Glioblastoma
Cells
In order to make possible the microglia/astrocytes–GB
crosstalk, some important mechanisms of transportation
and/or communication among those cells play an utmost role,
to name a few, the ATP Binding Cassette transporters (ABC
transporters) and the EVs. We will describe, below, in further
detail, the most important mechanisms of transportation and
communication among microglial/astrocytes–GB cells, and it is
also summarized in Figure 2.
ABC Transporters
The ABC transporter proteins are a superfamily of proteins,
located in biological membranes of most cells from varied species,
whose role is the active transport of a wide range of substances,
most notably the eﬄux of endo- and xenobiotics (Johnson and
Chen, 2017). These transporters are overexpressed in many
cancers, including gliomas, and are responsible for the eﬄuxion
of a varied repertoire of chemotherapeutic drugs from cancer
cells. The 49 currently known human ABC transporters have
been grouped into seven families, ranging from ABCA to ABCG,
depending on their sequence homology (Begicevic and Falasca,
2017).
In glioma, the most relevant ABC transporter proteins are
p-glycoprotein (ABCB1), MDR-associated protein-1 (ABCC1),
and breast cancer resistance protein (ABCG2) (Quezada et al.,
2011). Studies have shown that the ABCC1, ABCB1, and
ABCA13 are correlated with the level of glioma aggressiveness,
with these proteins being overexpressed in high-grade glioma
compared to low-grade astrocytoma (de Faria et al., 2008; Balça-
Silva et al., 2017a; Dréan et al., 2018).
Despite their role in cancer, the expression of the transporters
mentioned above has been documented in other TME cells,
mainly in capillary epithelial cells, which constitute BBB.
However, there is much less information on brain parenchymal
cells, such as microglia, oligodendrocytes, and astrocytes (Gibson
et al., 2012). One study that sought to link immune modulators
and expression of ABC transporters was conducted in a BV-2
mouse model for microglia function (Gibson et al., 2012). Resting
microglia phenotype, in a non-diseased brain, was shown to
express mRNAs for transporters ABCC1, ABCC4, ABCB1, and
ABCG2 with comparatively low ABCC5. When in vitro activation
of microglia was performed using LPS, the microglial cells had a
profound change in transporter expression with ABCC4, ABCB1,
and ABCG2 decreasing half-fold while ABCC1 and ABCC5 had
a 140 and 210% increase, respectively (Gibson et al., 2012).
Another study to determine the effect of specific cytokines
on transporters was carried out using IL-6 and TNF-α, two
proinflammatory cytokines, which are also produced by activated
microglia. In primary microglia cell cultures, administration of
these cytokines elicited opposing effects on ABCB1 expression,
inducing a slight decrease in its mRNA levels after IL-6
administration and a significant increase after TNF treatment at
both the gene and protein levels (Shi et al., 2012).
Additional roles are emerging for ABC proteins during the
interactions of cancer cells with TME entities. The transportation
of molecules into the TME, such as signaling lipids with
established roles in tumor biology (for instance, prostaglandins,
leukotrienes, and sphingosine-1-phosphate or SIP), and that are
known to have profound effects on immune cells (for instance,
microglia/macrophages), have been shown to be ABC transporter
substrates (Cole, 2014; Fletcher et al., 2016). This raises the
question of whether ABC transporter can mediate the eﬄux of
these molecules and how is it important in the context of cancer
and, in particular, cell–cell communication of populations within
the tumor mass. There are very few studies that have sought to
unravel the role played by ABC transporters in the interactions
between gliomas and microglia or astrocytes.
Comparative analysis of ABCG2 expression in primary
astrocytes and GSCs showed that ABCG2 is only expressed in
GSCs and not in normal astrocytes (Chen et al., 2017).
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FIGURE 2 | Transportation mechanism involved in glial cells and GB crosstalk. (A) GB cells express several ABC transporters, such as ABCB1, ABCC1, ABCG2 and
ABCC13, and ABCA13. GB cells express prostaglandins (PG), leukotrienes (LTs), and sphingosine-1-phosphate (S1P), which can be ABS transporters subtracts in
microglial/astrocytic cells. The astrocytes and microglial cells express ABCG1 and ABCG2. Other mechanism of cell–cell communication is through the EVs, such as
exosomes. GB miRNAs, namely the miR451, miR21, and miR-221, can be transferred through EVs to microglial cells. However, how can they be transferred to
astrocytes is still unclear. Also, EVs are a mechanism for GB to induce MT1–MMP expression in GB-associated microglia. Moreover, extracellular ATP promotes
microglia activation and induces the release of EVs in order to enable the communication between microenvironment cells. In fact, miR-9 released from Tat-stimulated
astrocytes can be taken up by microglial cells, which result in their migratory phenotype. (B) ABCG2 is only expressed in GB-stem-like cells. Also, GB-released EVs
can transport miRNAs, such as miR2. However, their role in astrocytic and microglial cells is not exploited. (C) Lactadherin (Lyd), syntenin-1(Syn-1), myristoylated
alanine-rich C-kinase substrate (MARCKS), integrin alpha-V and alpha-3 (αV and α3), and EGFR can be detected in the membrane of GB-released EVs.
Recently, Dréan et al. (2018) performed a study to verify the
expression of ABCA1, ABCA4, ABCA13, ABCC1, ABCC12,
ABCC13, and ABCG1 in cohort of 51 newly diagnosed
GB patients. They observed that GB overexpression of
ABCA13, ABCC1, and ABCC13 are correlated with GB
patient progression-free survival. Moreover, they also analyzed
the ABC transporters in GB bulk cells, namely, astrocytes and
microglial cells. They showed that ABCG1 and ABCG2 are
mainly expressed by astrocytes while microglial cells have high
expression of ABCG2 compared to the levels of ABCG1, but
no ABCA13 expression was observed in these cells (Dréan
et al., 2018). However, the differential relation and role of the
ABC transporters in these cells is not completely elucidated
(Figure 2).
So far, the experiments carried out have only shown effects
of immune modulators secreted by activated immune cells like
microglia/macrophages on the expression of ABC transporters.
The overall effect of transporter upregulation or downregulation
on the interactions between microglia or astrocytes and glioma,
especially those effects that lead to tumor progression, are still
under investigation.
Extracellular Vesicles
The cells can produce EVs that are constituted by a membrane-
limited vesicle that can be divided into three subclasses: apoptotic
bodies, microvesicles (MVs), and exosomes (Ciregia et al., 2017).
The differences between all the three EV types are dependent
and based on the origin and size of each one. The largest EVs,
normally observed in cell death mechanisms, have a size that
varies between this 1,000 and 5,000 nm. The MVs derived from
the external budding of the membrane can vary between 100 and
1,000 nm; and finally, the smallest vesicles (30–100 nm) are the
exosomes (Ciregia et al., 2017).
Among the EVs, the exosomes are the best described
and enabled via communication between cells involved in
many physiological processes, including its involvement in
pathological condition by activating signaling pathways and
changing components of the membrane and its neighbor cells
(Abels and Breakefield, 2016; Ciregia et al., 2017).
Almost all the body fluids of humans [i.e., cerebrospinal fluid
(CSF), blood plasma, saliva, or urine] have exosomes, so they
are considered a promising diagnostic and prognostic biomarkers
(Akers et al., 2015).
Regarding brain tumors, GB-derived MVs represent one of
the mechanisms by which cancer cells can modulate the TME
to a more permissive condition for growth and invasion (Dubois
et al., 2014).
Our group has recently shown the plasticity of the stem-like
cell state through the interconversion of more differentiated cells
into a dedifferentiated state (Balça-Silva et al., 2017b). In fact,
other authors mentioned that this plasticity could be mediated
by MVs in in vivo conditions (Quesenberry et al., 2015).
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In parallel, the downregulation of mRNA expression levels
of TIMP metallopeptidase inhibitor 1(TIMP1), TGF-β, and IL-
8 in exosomes is correlated with the survival of GB patients
after a vaccination with dendritic cell-derived exosomes, which
highlights a potential role of EVs in glioma immunotherapy
(Muller et al., 2015).
Regarding the miRNAs’ importance in gene regulation, it is
also known in literature that several microRNAs are found to be
encapsulated in EVs in the serum of glioma patients, which make
them potential circulating biomarkers for early diagnosis, tumor
staging, and prognosis. In fact, in serum-derived exosomes of
GB patients and CSF-derived EVs, the miR-21 and miR-221 were
shown to be highly enriched so that they may constitute potential
relevant biomarkers (Akers et al., 2013; Yang et al., 2017).
Taking into account the crosstalk between GAMs in
glioma, it is also important to highlight that recent studies
showed that microglia-derived exosomes in the brain could be
used as nanotherapeutic agents against glioma cells (Murgoci
et al., 2018). In fact, extracellular ATP promotes microglia
activation and induces the release of EVs, which can potentially
mediate intercellular communication between microglia and the
microenvironment (Drago et al., 2017). Furthermore, it was
also demonstrated that the crosstalk between GB and astrocytes
occurs through EVs. GB EV-treated NHAs had increased the
expression of IFN-γ, ILs 12, 1A, 8, and 1B, chemokine CXCL10,
and factor C5. Moreover, the conditioned medium of GB EV-
treated NHAs induces the growth of GB cells. Thus, miR-9
released from Tat-stimulated astrocytes can be taken up by
microglial cells, which result in their migratory phenotype.
Therefore, glial crosstalk via miRNAs released from EVs play
a crucial role mediating pathogenesis, which could eventually
lead to the development of novel therapeutic strategies aimed at
cushion neuropathogenesis (Yang et al., 2017).
HOW TO MANIPULATE
MICROGLIA/ASTROCYTES–
GLIOBLASTOMA
CROSSTALK
There are many efforts to overcome the GB’s resistance by finding
and testing new compounds that can be used as therapeutic
approaches. One of the main targets to these compounds are the
neighbor entities of GBs, such as the microglia and astrocytes,
since they have a great influence on the tumor progression
(Hambardzumyan et al., 2016; Matias et al., 2018; Roesch et al.,
2018).
We will present the most recent works that demonstrate
to be potential therapeutic approaches to target microglia
and astrocytes, which could turn off the immunosuppression
observed in GBs and decrease their progression.
According to the literature, the tumor progression is
facilitated by the immunosuppressive microenvironment created
by GB and GAMS crosstalk (Hambardzumyan et al., 2016).
In this regard, targeting microglial cells may be useful in
manipulating GB growth, especially the GSCs (Ye et al., 2012;
da Fonseca et al., 2016). Possibly, the therapeutic approach that
can be used by chemoattractant receptors/ligands blockage to
reduce GAMs recruitment, or even depleting or re-polarizing
to enrich the pro-inflammatory M1-like GAMs, is still under
discussion (Poon et al., 2017).
Among the therapeutic drugs targeting microglia in a
preclinical model, the blockage of CSF-1R signaling in glioma-
bearing mice, through the anti-CSF-1R antibody Pexidartinib
(PLX3397), resulted in a significant reduction tumor infiltration
of GAMs and, consequently, a decrease in tumor volume, as
well as an apparent increase of the survival time of treated mice
(Pyonteck et al., 2013). However, later on, Butowski et al. (2016)
showed that PLX3397 was well tolerated in patients and readily
crossed the blood–tumor barrier but showed no efficacy.
Also, the CSF-R1 inhibitor BLZ945, in glioma-bearing mice,
demonstrated reduced expression of M2-like markers in GAMs,
which – after the administration of the insulin-like growth factor
1 (IGF-1) and phosphatidylinositol-4,5-bisphosphate 3-kinase
(PI3K) antagonist – reduced the tumor progression, and an
increase in the survival time of mice was observed (Coniglio
et al., 2012). In agreement with that, Quail et al. (2016) concluded
that the dual inhibition of IGF-1R/PI3K and CSF-1R significantly
prolonged overall survival rate in recurrent glioma in mice.
The chemokines and their receptors are highly expressed in
microglial cells, and they are extremely important to tumor
progression (Zhao et al., 2015; Laudati et al., 2017; Jin et al.,
2018). Thus, they may constitute a good target to decrease
the microglia and tumor interaction. For that reason, many
studies have been made to discover new inhibitors of chemokines
receptors. Recently, it has been shown that the CCR5 blocker
MRV was able to reduce the M2-like phenotype by reducing the
ARG-1 and IL-10 proteins and promoting the upregulation of
M1-like markers, such as NO and IL-1β in microglial cells treated
in GB-conditioned medium (Laudati et al., 2017). The inhibition
of the SDF-1 receptor (CXCR4) by using AMD3100 is another
approach to target GAMs. Also, the inhibition of SDF in myeloid
cells was performed using the Plerixafor in multiple myeloma and
lymphoma, which constitutes a huge promise regarding glioma
(Dillmann et al., 2009; Rios et al., 2016).
In the search to find an efficient anti-angiogenic therapy
to treat GB, it was recently demonstrated that the survival of
GB-xenografts mice on the isolated anti-VEGF blockade was
derived from the double blockade of Ang-2/increased VEGF.
This dual blockade induced the reprogramming of GAMs from
the pro-tumor M2-like phenotype toward the antitumor M1-like
phenotype (Kloepper et al., 2016).
Moreover, another antagonist of CXCR4, the peptide R,
decreases the tumor mass of GB-xenotransplanted cells and
reduces the CD11/CD68-positive cells in peritumoral zone of the
tumor. In addition, the peptide R induces the M1-like phenotype
in microglial cells by increasing the iNOS levels (Mercurio et al.,
2016).
In parallel, AXL is highly expressed by GBs and microglia
secrete the protein S (PROS1) responsible for phosphorylating
AXL, which consequently induces the aggressiveness of GBs.
Thus, Sadahiro et al. (2018) verified if the combination of a
specific inhibitor of AXL (BGB324) with Nivolumab (antibody
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against PD-1) could be used for GB treatment. They showed
increased survival in mice treated with BGB324 and Nivolumab.
Further, in this study, the authors observed that protein S
(PROS1)/tyrosine-protein kinase (AXL) pathway is involved in
extrinsic immune microenvironment by reduction of microglia
infiltration after treatment (Sadahiro et al., 2018).
Moreover, in vitro and in vivo studies showed that the
high expression of Nrp1 is correlated with the poor prognosis
by inducing the proliferation and migration of GB cells.
It has been shown that the Nrp1 is important to induce
M2-like phenotype in microglia. Studies showed that the
specific inhibitor of Nrp1 named EG00229 reduced tumor
growth. These findings suggest that targeting Nrp1 could be
a useful therapeutic approach for GBs since the EG00229
reduces Nrp1 expression and induces the M1 polarized
phenotype on microglial cells, which consequently suppress the
vascularization and proliferation of tumor cells (Miyauchi et al.,
2016).
The phenolic compound, chlorogenic acid (CHA), has an
anti-tumor effect in multiple malignant tumors, including
GB. In vitro studies showed that CHA inhibited GB growth
and induced apoptosis of GB cells. CHA promotes M1
polarization by increasing the levels of iNOS, MHC II, and
CD11c and, consequently, reduces the M2 polarized markers
by decreasing ARG and CD206 levels. Besides, the CHA
reduced the tumor size and increased the number of CD11c+
M1 GAMs compared to CD206+ M2 GAMs in tumor tissue
from mice orthotropic xenograft models of GB (Xue et al.,
2017).
Histopathological studies demonstrated an increase of
infiltrated microglia in chondroitin sulfate proteoglycan 4
(CSPG4), which is highly expressed in GB samples, co-expressing
TNF-α. Recently, regarding the new era of immunotherapy,
Pellegatta et al. (2018) showed that CSPG4 can be targeted by
CAR-T cells, promoting the control of tumor growth by inducing
TNF-α expressed from microglial cells, leading to tumor cells
death.
Together with microglial cells, astrocytes are also a crucial part
of the TME cells that are involved in similar interactions with the
tumor cells influencing its malignancy.
In this sense, it is known that hypoxic microenvironment
maintains the malignant profile of GBs through the HIF-1α
expression. However, in a hypoxic microenvironment, there are
still astrocytes, which can release high levels of CCL20 that,
upon binding to the GB receptor CCR6, induce the expression
of HIF-1α (Jin et al., 2018). The authors noticed an increase in
the tumor mass that was accompanied by a high vascularization
and increased levels of HIF-1α in mice injected with GB cells
compared to CCR6-knockdown GB xenografts. These results
suggest that, in a hypoxic microenvironment, GB cells growth
is dependent on the CCL20 derived from astrocytes. Thus, the
CCL20/CCR6 signaling could be a potential therapeutic target for
GB treatment (Jin et al., 2018).
Some evidence support the idea that astrocytes can influence
the tumor chemoresistance by protecting GB cells to TMZ
or Vincristine (VCR) cytotoxicity by increasing the CX43.
Therefore, it can be considered a potential target for the
CX43-mediated GJCs between GB/astrocytic cells, and so the
combination of the CX43 inhibitor with TMZ or VCR could be
a successful therapy to GBs (Chen et al., 2015).
On the other hand, Hong et al. (2015) showed that the gap
junctions play a role during glioma and astrocyte interactions
by allowing the transference of miRs from glioma cells to
astrocytes. So, the miR-4519 and miR-5096-transferred from GB
to astrocytes through CX43 induce the pro-invasive phenotype
in astrocytes (Hong et al., 2015). This evidence supports the idea
that CXs and miRs may be a useful therapeutic target to decrease
the interaction between astrocyte and GB and, consequently,
decrease tumor progression.
As previously mentioned, the EVs are used by tumor cells
as carriers to communicate with other cells from TME, such
as astrocytes (Oushy et al., 2018). GB EVs modulate NHAs by
increasing their migratory capability and inducing the cytokine
production (as ILs 4, 10, and CCL2), which consequently
TABLE 2 | Microglial/astrocytic cells – therapeutic targets in GB.
Therapy Therapeutic target Target cells Study phase References
Pexidartinib CSF-1R blockade Microglia Phase I clinical trials Butowski et al., 2016
BLZ945 CSF-1R inhibition
combined with IGF-1R and
PI3K blockade
Microglia Preclinical studies Coniglio et al., 2012; Quail et al., 2016
Maraviroc (MRV) CCR5 blockade Microglia Preclinical studies Laudati et al., 2017
AMD3100 SDF-1 receptor (CXCR4)
inhibition
Microglia Preclinical studies Dillmann et al., 2009
Peptide R SDF-1 receptor (CXCR4)
inhibition
Microglia Preclinical studies Mercurio et al., 2016
BGB324 and Nivolumab AXL and PD-1 inhibition Microglia Preclinical studies Sadahiro et al., 2018
EG00229 Nrp1 blockade Microglia Preclinical studies Miyauchi et al., 2016
CART cells CSPG4 inhibition Microglia Preclinical studies Pellegatta et al., 2018
Chlorogenic acid (CHA) Arg and CD206 Microglia Preclinical studies Xue et al., 2017
CCL20 CCL20/CCR6 signaling
inhibition
Astrocytes Preclinical studies Jin et al., 2018
CX43 inhibitor with TMZ or VCR CX43 Astrocytes Preclinical studies Chen et al., 2015
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stimulate the tumor growth (Oushy et al., 2018). Therefore,
finding a way to control the release of these GB EVs may be one
possible strategy to decrease the tumor progression.
The principal studies previously mentioned regarding
microglia/astrocytes GB crosstalk-therapeutic targets are
summarized in Table 2.
CONCLUSION AND FUTURE
PERSPECTIVES
During recent years, many efforts have been made to understand
the heterogeneity of microglia/astrocytes. However, still little
is known about the complex interaction and dynamics among
microglia/astrocytes and tumor, such as GB, and how this
crosstalk can influence tumor growth and patient’s outcome.
Nevertheless, to successfully improve GB patient survival, more
in-depth knowledge is needed regarding the crosstalk between
those TME cells.
In this review, we discussed the several factors and proteins
already known that can modulate the activity of microglia
or astrocytes during GB progression. Cytokines, chemokines,
neurotrophic, and morphogenic factors can be associated with
recruitment of tumor parenchyma cells, such as microglia and
astrocytes, by the modulation of their phenotypes in order to
influence tumor growth. In parallel, metabolic changes are known
to be one of the more important engines for cell mechanisms,
which include the cell proliferation and migration. In this regard,
it is necessary to clarify the role of metabolites and enzymes
of the cycle Krebs, as well as the glycolysis components during
microglia/astrocytes–GB crosstalk. Also, the modulation of the
cytoskeleton and ECM proteins is crucial for this crosstalk.
However, more studies are needed to understand the underlying
morphological changes during M1 and M2 polarization in
microglia and astrocyte reactivity.
On the other hand, the miRNAs have been described
as positive or negative regulators of this crosstalk, such as
miR451/miR21 that are involved in microglia polarization into
M1/M2-like phenotype. Thus, the identification of new miRNAs
that can regulate this interaction is one of the main focus for
future investigations.
The communication between microglial/astrocytes and GBs
cells can be performed through the EVs. In fact, EVs can
participate in this interaction through the transport of several
factors, such as miRNAs or even morphogenic factors, such
as the Shh or Wnt. Also, the ABC transporters have a huge
importance in GB resistance. Additionally, these transporters
may also be involved in the transference of factors that modulate
microglia/astrocytes behavior. Thus, it seems to us that the
development of novel therapies, targeting factors/receptors that
modulate the phenotype of microglial and astrocyte cells toward
a proinflammatory behavior, may be a useful approach for GB
patients. Table 2 represents some studies that are in clinical
stages, and their results, such as PLX3397, have not been very
promising. However, some studies have demonstrated the efficacy
of compounds targeting membrane receptors on microglial
cells, such as Plerixafor, peptide R, and the combination of
BGB324 with Nivolumab. Using the natural ability of the EVs
as transporters, it may be possible to use them as drug delivery
strategies, thus targeting the microglial and astrocytic cells.
In a clinical setting, it seems to be crucial to identify new
potential targets in the microglia/astrocytes–GB crosstalk and,
ultimately, develop a new range of therapeutic approaches,
hopefully contributing in future to a better outcome for patients
with an aggressive and deadly tumor, such as GB.
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